All News

    177Lu-edotreotide May Delay Progression in Neuroendocrine Tumor Subset

    March 7th 2025, 10:00pm

    Article

    177Lu-edotreotide shows potential to extend progression-free survival in patients with grade 1 or 2 somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

    The Dawn of a New Era in Cancer Treatment

    March 7th 2025, 8:00pm

    Article

    New advancements in cancer treatment are reducing the need for radical surgeries, offering organ-sparing therapies and enhancing survivorship care and support for patients.

    Challenging Cancer Stereotypes While Living with Follicular Lymphoma

    March 7th 2025, 6:00pm

    Article

    Living with follicular lymphoma, I challenge common misconceptions about cancer, highlighting the unique and varied experiences of patients with cancer.

    BRCA1/2 Mutations May Associate With Better Chemo Response in TNBC

    March 7th 2025, 4:00pm

    Article

    Among patients with early-stage triple-negative breast cancer, a beneficial pathologic complete response rate was higher in patients with BRCA1/2 mutations.

    Calquence Combo May Improve Outcomes in Chronic Lymphocytic Leukemia

    March 7th 2025, 2:00pm

    Article

    Calquence plus Venclexta with or without Gazyva significantly improved progression-free survival in patients with untreated CLL.

    Presurgical Opdivo Plus Yervoy Has Potential Clinical Benefit in NSCLC

    March 6th 2025, 10:00pm

    Article

    Among patients with resectable non-small cell lung cancer, Opdivo plus Yervoy has displayed potential long-term clinical benefits versus chemotherapy.

    How the FDA Approval of Imfinzi Advances Small Cell Lung Cancer Treatment

    March 6th 2025, 8:00pm

    Video

    The FDA has approved Imfinzi for some adults with limited-stage small cell lung cancer.

    FDA Approval of Ensacove Adds to the Toolkit for ALK-Positive NSCLC

    March 6th 2025, 8:00pm

    Video

    An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung cancer.

    What the FDA Approval of Bizengri Means for Patients With NRG1-Positive NSCLC

    March 6th 2025, 8:00pm

    Video

    The FDA granted its first approval for a systemic therapy for patients with non-small cell lung cancer with an Neuregulin 1 gene fusion.

    What’s On the Horizon for Small Cell Lung Cancer Research?

    March 6th 2025, 8:00pm

    Video

    On the heels of two FDA approvals in lung cancer treatments, what innovations are next?